Dendritic Cell Cancer Vaccine Market to Reflect Robust Expansion During 2023-2030: Grand View Research Inc.

 Dendritic Cell Cancer Vaccine Market Growth & Trends

The global dendritic cell cancer vaccine market size is expected to reach USD 1.46 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.18% from 2023 to 2030. The rising prevalence of cancer and technological improvement such as drug innovation related to cancer are driving the market growth. According to the WHO, cancer is the leading cause of mortality globally, accounting for around 10 million deaths in 2020.

Immunotherapy is a new approach that strengthens an individual’s immunity to combat different types of carcinoma. Dendritic cell-based immunotherapy vaccination is a well-known and approved approach for enhancing the potential of the immune system to eliminate tumor cells. Many studies are carried out to gauge the efficacy of dendritic cell cancer vaccines. For instance, in June 2020, UbiVac, Inc. signed into a clinical trial collaboration with Bristol Myers Squibb for evaluation of the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product (DPV-001), a dendritic cell-targeted micro-vesicle containing short-lived protein vaccine to explore autophagy, in combination with anti-OX40 (by Bristol Myers Squibb) along with sequenced administration of nivolumab.

Moreover, wide applications of cancer vaccines to boost the immune system are some of the driving factors for market growth. Cancer vaccines are appropriately recognizing and effectively react to antigens associated with carcinoma and kill the carcinogenic cells. They progressively reduce the growth of tumorous cells in the body and induce immunity in an individual to effectively cease the chances of a relapse of cancer condition.

Rising clinical trial activity along with novel product launches create the growth opportunity for market growth. As of November 2022, more than 80 dendritic cell cancer vaccines are under clinical trials. In addition, in June 2021, SPAG9, India's First Indigenous Tumor Antigen, Received a Trademark from DBT-NII. Dendritic cell (DC)-based immunotherapy is being used with ASPAGNIITM for cervical, ovarian, and breast cancers.

Furthermore, key companies in the market undertaking various strategic initiatives to introduce novel are expected to drive the market. For instance, in June 2020, Saint-Gobain Life Sciences signed into a joint collaboration with Kanyr Pharma Inc., the RI-MUHC, and McGill University for research on cancer vaccines based on dendritic cells using single-use culture containers by Saint-Gobain for R&D, clinical-scale and commercial phase production of vaccines.

Request a free sample copy or view the report summary: Dendritic Cell Cancer Vaccine Market Report

Dendritic Cell Cancer Vaccine Market Report Highlights

• By product, the Sipuleucel-T (Provenge) is expected to occupy the largest share of market space due to its advantages in the treatment of castrate-resistant prostate carcinoma.
• By end-use, the adult segment is expected to grow rapidly over the forecast period owing to the rise in the incidence of carcinoma across the globe. The rise in the demand for personalized medicine for the treatment of cancer, also positively impacts the growth of this segment.
• North America dominated the global market in 2022, owing to the rising prevalence of cancers, increasing healthcare expenditure, and rising support for oncology research.
• The Asia Pacific is expected to grow considerably in the future due to the rising prevalence of cancers and high population density. Moreover, key market players are working towards entering the Asia Pacific market with their dendritic cell vaccine expertise. For instance, in May 2021, BGI signed an agreement with the Ethiopian Biotechnology Institute to carry out pilot-scale testing of HPV genotyping to establish a novel technique for HPV screening, diagnosis, and treatment.

Access Press Release@ https://www.grandviewresearch.com/press-release/global-dendritic-cell-cancer-vaccine-market

Dendritic Cell Cancer Vaccine Market Segmentation

Grand View Research has segmented the global dendritic cell cancer vaccine market report based on products, end-use, and region.

Dendritic Cell Cancer Vaccine Product Outlook (Revenue, USD Million, 2018 - 2030)

• CreaVax
• Sipuleucel-T (Provenge)
• Other

Dendritic Cell Cancer Vaccine End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pediatrics
• Adults

Dendritic Cell Cancer Vaccine Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

List of Key Players in Dendritic Cell Cancer Vaccine Market

• GlaxoSmithKline plc,
• 3M Company
• Activartis
• Batavia Bioservices,
• Argos Therapeutics
• Sanpower Corporation
• Elios Therapeutics
• DanDrit Biotech
• DCPrime
• ImmunoCellular Therapeutics

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.